Detalhe da pesquisa
1.
Type I interferon and cancer.
Immunol Rev
; 321(1): 115-127, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37667466
2.
The cytokine milieu compromises functional capacity of tumor-infiltrating plasmacytoid dendritic cells in HPV-negative but not in HPV-positive HNSCC.
Cancer Immunol Immunother
; 70(9): 2545-2557, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33569630
3.
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Gynecol Oncol
; 162(3): 652-660, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34294416
4.
Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients.
Haematologica
; 105(7): 1868-1878, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582537
5.
Tolerogenic Dendritic Cells from Poorly Compensated Type 1 Diabetes Patients Have Decreased Ability To Induce Stable Antigen-Specific T Cell Hyporesponsiveness and Generation of Suppressive Regulatory T Cells.
J Immunol
; 198(2): 729-740, 2017 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27927966
6.
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.
Cancer Immunol Immunother
; 67(1): 89-100, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28948333
7.
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.
Blood
; 128(26): 3113-3124, 2016 12 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-27802968
8.
High hydrostatic pressure induces immunogenic cell death in human tumor cells.
Int J Cancer
; 135(5): 1165-77, 2014 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24500981
9.
Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients.
Clin Immunol
; 153(1): 49-55, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24709112
10.
Tissue contexture determines the pattern and density of tumor-infiltrating immune cells in HPV-associated squamous cell carcinomas of oropharynx and uterine cervix.
Transl Oncol
; 41: 101884, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242007
11.
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer.
Nat Commun
; 15(1): 2528, 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38514660
12.
Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells.
Int J Cancer
; 132(5): 1070-9, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22865582
13.
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy.
J Exp Med
; 204(4): 831-40, 2007 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-17389240
14.
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.
J Immunother Cancer
; 11(2)2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36822672
15.
Type I interferon signaling in malignant blasts contributes to treatment efficacy in AML patients.
Cell Death Dis
; 14(3): 209, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36964168
16.
Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Oncoimmunology
; 12(1): 2219591, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37284695
17.
SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity.
Front Immunol
; 13: 989895, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36300122
18.
Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents.
Trends Cancer
; 8(5): 426-444, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35181272
19.
Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34992091
20.
An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors.
Clin Cancer Res
; 28(14): 3053-3065, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35536547